ArticleInfection and immunity2020
MicroRNA-155 Deficiency Exacerbates Trypanosoma cruzi Infection.
Article in Infection and immunity, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 28 citations in OpenAlex.
- SBC Guideline on the Diagnosis and Treatment of Patients with Cardiomyopathy of Chagas Disease - 2023.Arquivos brasileiros de cardiologia · 2023Guideline
- Exploratory small RNA sequencing of human placental miRNAs identifies candidates associated with congenital transmission of Trypanosoma cruzi.Research square · 2026Article
- Extracellular Vesicles Derived from Trypanosomatids: The Key to Decoding Host-Parasite Communication.International journal of molecular sciences · 2025Review
- MicroRNAs orchestrating host and vector-borne protozoan interactions: bridging immune modulation and cross-species communication.Frontiers in immunology · 2025Review
- Animal models for exploring Chagas disease pathogenesis and supporting drug discovery.Clinical microbiology reviews · 2024Review
- Protective role of TRPV1Brain, behavior, & immunity - health · 2024Article
- Role of microRNAs in Immune Regulation with Translational and Clinical Applications.International journal of molecular sciences · 2024Review
- Discovery of circulating miRNAs as biomarkers of chronic Chagas heart disease via a small RNA-Seq approach.Scientific reports · 2024Article
- MiRNA-146a-A Key Player in Immunity and Diseases.International journal of molecular sciences · 2023Review
- Treatment with benznidazole and pentoxifylline regulates microRNA transcriptomic profile in a murine model of Chagas chronic cardiomyopathy.PLoS neglected tropical diseases · 2023Article
- Cytokine Networks as Targets for Preventing and Controlling Chagas Heart Disease.Pathogens (Basel, Switzerland) · 2023Review
- MicroRNAs in T Cell-Immunotherapy.International journal of molecular sciences · 2022Review
- Circulating MicroRNAs and myocardial involvement severity in chronic Chagas cardiomyopathy.Frontiers in cellular and infection microbiology · 2022Article
- Epigenetic regulation of transcription factor binding motifs promotes Th1 response in Chagas disease cardiomyopathy.Frontiers in immunology · 2022Article
- Multi-therapeutic strategy targeting parasite and inflammation-related alterations to improve prognosis of chronic Chagas cardiomyopathy: a hypothesis-based approach.Memorias do Instituto Oswaldo Cruz · 2022Article
- Circulating miR-146a as a possible candidate biomarker in the indeterminate phase of Chagas disease.Biological research · 2021Article
- MicroRNA-155 contributes to host immunity against Toxoplasma gondii.Parasite (Paris, France) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
Chagas disease, caused by the intracellular protozoan parasite
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.